Sin Hang Cheng

Ms. Sin Hang Cheng

Peking University Third Hospital, Beijing, China
+1

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
Sin Hang ChengSin Hang Cheng
Sin Hang Cheng
YZYin Zhang
Yin Zhang
WLWenqiang Li
Wenqiang Li
GXGuoshuai Xu
Guoshuai Xu
Jun QuJun Qu
Jun Qu
The gut microbiome has emerged as a key modulator of therapeutic responses in gastrointestinal cancers. This narrative review critically summarizes how specific pathogenic bacteria—including Fusobacterium nucleatum, Bacteroides fragilis, and Gammaproteobacteria—have been implicated in chemoresistance through autophagy activation, suppression of endoplasmic reticulum stress-mediated cell death, inhibition of pyroptosis, induction of cancer-cell quiescence, and direct drug metabolism. In immunotherapy, the microbiome profoundly influences immune checkpoint inhibitor efficacy; Akkermansia muciniphila and Clostridium butyricum enhance anti-tumor immunity via the cGAS-STING pathway and the secD/GRP78/IL-6 axis, while microbial metabolites such as succinate, 4-hydroxyphenylacetic acid, and spatially depleted butyrate promote resistance through CD8+ T-cell exhaustion and immunosuppressive cell recruitment. In gastric cancer, Helicobacter pylori and non-Helicobacter gastric microbiota shape chemotherapy and immunotherapy responses; in hepatocellular carcinoma, the gut–liver axis and bile acid metabolism influence immune checkpoint blockade; and in pancreatic ductal adenocarcinoma, intratumoral Gammaproteobacteria and metabolites such as trimethylamine N-oxide and indole-3-acetic acid modulate gemcitabine resistance and immunotherapy efficacy. We further evaluate emerging microbiome-targeted strategies including fecal microbiota transplantation, engineered probiotics, and bacteriophage therapy, and discuss challenges in clinical translation. By elucidating the molecular mechanisms of microbiome-mediated therapy modulation, we propose a hypothesis-generating, evidence-graded framework for future prospective validation in microbiome-guided precision oncology.